Novo Nordisk and Eli Lilly weight-loss drugs still work at smaller doses, study finds

A study found that Novo Nordisk's and Eli Lilly's weight-loss drugs remain effective at smaller doses, a finding that could affect dosing and supply economics for the two leading GLP-1 makers.

Detected & updated continuously · Source: Nebula